Statements (15)
Predicate | Object |
---|---|
gptkbp:instanceOf |
gptkb:biotechnology
|
gptkbp:acquiredBy |
gptkb:Pfizer
|
gptkbp:acquisitionYear |
2022
|
gptkbp:focusesOn |
gptkb:respiratory_syncytial_virus_(RSV)
antiviral therapies |
gptkbp:foundedIn |
2011
|
gptkbp:founder |
Ken Powell
Stuart Cockerill |
gptkbp:headquartersLocation |
gptkb:London,_United_Kingdom
|
https://www.w3.org/2000/01/rdf-schema#label |
ReViral
|
gptkbp:leadProduct |
RV521
sisunatovir |
gptkbp:website |
https://www.reviral.co.uk/
|
gptkbp:bfsParent |
gptkb:Novo_Holdings
|
gptkbp:bfsLayer |
7
|